Elizabeth Tan-Chiu

18.4k total citations · 4 hit papers
48 papers, 8.7k citations indexed

About

Elizabeth Tan-Chiu is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Elizabeth Tan-Chiu has authored 48 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 18 papers in Cancer Research and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Elizabeth Tan-Chiu's work include HER2/EGFR in Cancer Research (21 papers), Breast Cancer Treatment Studies (15 papers) and Cancer Treatment and Pharmacology (13 papers). Elizabeth Tan-Chiu is often cited by papers focused on HER2/EGFR in Cancer Research (21 papers), Breast Cancer Treatment Studies (15 papers) and Cancer Treatment and Pharmacology (13 papers). Elizabeth Tan-Chiu collaborates with scholars based in United States, Belgium and Spain. Elizabeth Tan-Chiu's co-authors include Norman Wolmark, Bernard Fisher, D. Lawrence Wickerham, Joseph P. Costantino, Victor G. Vogel, Maureen Kavanah, James N. Atkins, Nikolay Dimitrov, Mary B. Daly and Walter M. Cronin and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Biochemistry.

In The Last Decade

Elizabeth Tan-Chiu

47 papers receiving 8.4k citations

Hit Papers

4 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1998 4.0k citations Bernard Fisher, Joseph P. Costantino et al. JNCI Journal of the National Cancer Institute profile →
Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31

2005 568 citations Elizabeth Tan-Chiu, Greg Yothers et al. Journal of Clinical Oncology profile →
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

2010 568 citations Howard A. Burris, Hope S. Rugo et al. Journal of Clinical Oncology profile →
erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer

1998 515 citations Soonmyung Paik, John Bryant et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elizabeth Tan-Chiu United States	22	5.2k	3.2k	3.2k	1.5k	1.5k	48	8.7k
Robert Paridaens Belgium	55	6.3k 1.2×	3.6k 1.1×	3.3k 1.1×	1.8k 1.2×	877 0.6×	307	9.9k
Nicholas J. Robert United States	44	6.7k 1.3×	4.1k 1.2×	2.2k 0.7×	2.0k 1.4×	1.8k 1.2×	181	10.0k
L. Mauriac France	46	8.0k 1.6×	5.5k 1.7×	4.0k 1.3×	1.5k 1.0×	1.2k 0.8×	171	11.5k
Silvana Martino United States	49	9.2k 1.8×	6.6k 2.0×	3.1k 1.0×	2.0k 1.4×	1.4k 1.0×	125	12.9k
Tommy� Fornander Sweden	45	2.9k 0.6×	2.6k 0.8×	2.1k 0.7×	1.2k 0.8×	767 0.5×	133	6.5k
Karen N. Price Switzerland	50	5.8k 1.1×	4.9k 1.5×	2.6k 0.8×	1.4k 0.9×	861 0.6×	103	9.1k
Grazia Arpino Italy	37	4.2k 0.8×	2.8k 0.9×	1.6k 0.5×	1.7k 1.2×	867 0.6×	157	6.7k
Jacques Bonneterre France	44	5.1k 1.0×	2.8k 0.9×	1.5k 0.5×	1.9k 1.3×	730 0.5×	257	8.0k
Gershon Y. Locker United States	30	6.1k 1.2×	3.0k 0.9×	2.1k 0.7×	2.2k 1.5×	498 0.3×	76	9.5k
Bent Ejlertsen Denmark	44	3.9k 0.7×	2.8k 0.9×	1.5k 0.5×	1.3k 0.9×	551 0.4×	252	6.4k

Countries citing papers authored by Elizabeth Tan-Chiu

Since Specialization

Citations

This map shows the geographic impact of Elizabeth Tan-Chiu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth Tan-Chiu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth Tan-Chiu more than expected).

Fields of papers citing papers by Elizabeth Tan-Chiu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth Tan-Chiu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth Tan-Chiu. The network helps show where Elizabeth Tan-Chiu may publish in the future.

Co-authorship network of co-authors of Elizabeth Tan-Chiu

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth Tan-Chiu. A scholar is included among the top collaborators of Elizabeth Tan-Chiu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth Tan-Chiu. Elizabeth Tan-Chiu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lim, Bora, David A. Potter, Mohamad A. Salkeni, et al.. (2021). Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer. Clinical Cancer Research. 27(12). 3329–3338. 12 indexed citations

Pegram, Mark D., Igor Bondarenko, Hirotaka Iwase, et al.. (2018). PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study. British Journal of Cancer. 120(2). 172–182. 50 indexed citations

Pegram, Mark D., Elizabeth Tan-Chiu, Amy Freyman, et al.. (2017). A randomized, double-blind study of PF-05280014 (a potential trastuzumab biosimilar) vs trastuzumab, both in combination with paclitaxel, as first-line treatment for HER2-positive metastatic breast cancer. Annals of Oncology. 28. v74–v75. 13 indexed citations

Miles, David, S. B. Kim, Thierry Velu, et al.. (2016). First-line cobimetinib (C) + paclitaxel (P) in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and tumoral immune cell infiltration data from the phase 2 COLET study. Annals of Oncology. 27. vi89–vi89.

Hurvitz, Sara A., Florence Dalenc, Mario Campone, et al.. (2013). A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Research and Treatment. 141(3). 437–446. 58 indexed citations

Brufsky, Adam, Musa Mayer, Hope S. Rugo, et al.. (2011). Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER. Clinical Cancer Research. 17(14). 4834–4843. 283 indexed citations

Burris, Howard A., Hope S. Rugo, Svetislava J. Vukelja, et al.. (2010). Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy. Journal of Clinical Oncology. 29(4). 398–405. 568 indexed citations breakdown →

Rugo, Hope S., Peter A. Kaufman, Elizabeth Tan-Chiu, et al.. (2009). Survival of patients with HER2+ metastatic breast cancer and use of trastuzumab following progression: analysis of RegistHER.. Cancer Research. 69(2_Supplement). 3142–3142. 7 indexed citations

Yardley, Denise A., Peter A. Kaufman, Musa Mayer, et al.. (2007). registHER: Patient characteristics, treatment patterns, and preliminary outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR+) metastatic breast cancer (MBC). Journal of Clinical Oncology. 25(18_suppl). 21007–21007. 1 indexed citations

10.

Wapnir, Irene, Stewart Anderson, Eleftherios P. Mamounas, et al.. (2006). Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Five National Surgical Adjuvant Breast and Bowel Project Node-Positive Adjuvant Breast Cancer Trials. Journal of Clinical Oncology. 24(13). 2028–2037. 346 indexed citations

11.

Brufsky, Adam, Kenneth R Fox, Mauro Orlando, et al.. (2006). Phase II study of gemcitabine (Gem) and trastuzumab (T) combination therapy in first line metastatic breast cancer (MBC) patients (pts) with HER2 overexpression. Journal of Clinical Oncology. 24(18_suppl). 10591–10591. 6 indexed citations

12.

Brufsky, Adam, W G Harker, J. Thaddeus Beck, et al.. (2006). Zoledronic Acid Inhibits Adjuvant Letrozole–Induced Bone Loss in Postmenopausal Women With Early Breast Cancer. Journal of Clinical Oncology. 25(7). 829–836. 236 indexed citations

13.

Tan-Chiu, Elizabeth, Greg Yothers, Edward H. Romond, et al.. (2005). Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31. Journal of Clinical Oncology. 23(31). 7811–7819. 568 indexed citations breakdown →

14.

Franco, Sandra, Alejandra Perez, Elizabeth Tan-Chiu, et al.. (2005). Preliminary results of a multicenter phase II trial of neoadjuvant docetaxel, carboplatin and capecitabine for inflammatory and locally advanced breast cancer (LABC). Journal of Clinical Oncology. 23(16_suppl). 876–876. 2 indexed citations

15.

Franco, Sandra, et al.. (2004). Response to fulvestrant in heavily pretreated postmenopausal women:a single-center experience. Breast Cancer Research and Treatment. 88(2). 103–108. 27 indexed citations

16.

Wang, Jingjing, et al.. (2004). Lower-Category Benign Breast Disease and the Risk of Invasive Breast Cancer. JNCI Journal of the National Cancer Institute. 96(8). 616–620. 79 indexed citations

17.

Paik, Soonmyung, Jennifer Bryant, Elizabeth Tan-Chiu, et al.. (2002). Real-World Performance of HER2 Testing--National Surgical Adjuvant Breast and Bowel Project Experience. JNCI Journal of the National Cancer Institute. 94(11). 852–854. 375 indexed citations

18.

Reís, Steven E., et al.. (2001). Cardiovascular Effects of Tamoxifen in Women With and Without Heart Disease: Breast Cancer Prevention Trial. JNCI Journal of the National Cancer Institute. 93(1). 16–21. 113 indexed citations

19.

Dignam, James J., et al.. (1999). Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17. Cancer. 86(3). 429–438. 380 indexed citations

20.

Vogt, Andreas, Jiazhi Sun, Yimin Qian, et al.. (1995). Burkitt Lymphoma Daudi Cells Contain Two Distinct Farnesyltransferases with Different Divalent Cation Requirements. Biochemistry. 34(38). 12398–12403. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact